Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to provide
the FDA authority to require importers to destroy FDA-regulated
products refused entry into the U.S. that pose public health
concerns. The bill also prohibits the unauthorized movement of
items the secretary has designated for destruction.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2715 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearings were used to develop or consider H.R. 2715:
On February 6, 2025, the Subcommittee on
Health held a hearing on H.R. 2715. The title of the
hearing was ``Combating Existing and Emerging Illicit
Drug Threats.'' The Subcommittee received testimony
from:
Sheriff Michael Bouchard, Vice
President of Government Affairs, Major County
Sheriffs Association;
Raymond Cullen, Family Advocate;
Timothy Westlake, MD, FFSMB,
FACEP, Emergency Medicine Physician, ProHealth
Care Oconomowoc Memorial Hospital;
Regina LaBelle, JD, Professor
and Director, Master of Science in Addiction
Policy and Practice, Georgetown University;
and,
Deepa Camenga, MD, MHS, FAACP,
Chair, Committee on Substance Use and
Prevention, American Academy of Pediatrics.
On March 26, 2026, the Subcommittee on
Health held a legislative hearing on H.R. 2715. The
title of the hearing was ``Policies to Protect our
Communities from Illicit Drug Threats.'' The
Subcommittee received testimony from:
Scott Oulton, President,
INTR3PID Solutions LLC;
K. Fred Gingrich II, DVM,
Executive Director, American Association of
Bovine Practitioners;
Dennis Lemma, Sheriff, Seminole
County, Florida, and Former President of the
Major County Sheriffs of America;
Nabarun Dasgupta, PhD, MPH,
Senior Scientist and Gillings Innovation
Fellow, University of North Carolina at Chapel
Hill; and,
Yngvild Olsen, MD, MPH, Former
Director of the Center for Substance Abuse
Treatment, Substance Abuse and Mental Health
Services Administration, and National Advisor,
Manatt Health.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2715 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Destruction of
Hazardous Imports Act.''
Section 2. Destruction of certain refused articles
Section 2 amends section 801 of the FD&C Act to provide FDA
the authority to require that the owner or consignee of a
refused entry that is deemed by the Secretary of Health and
Human Services to present a significant public health concern
to cover the cost of storage and destruction of such article.
Additionally, it provides for due process to the owner or
consignee of an article subject to a destruction order, which
shall include notice and an opportunity to appear before the
Secretary to testify on the destruction order.
In addition to prohibiting the act of introducing an
article subject to a destruction order into interstate
commerce, this section directs FDA to promulgate final
regulations to implement the amendments made by this section.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (new matter is
printed in italics and existing law in which no change is
proposed is shown in roman):
FEDERAL FOOD, DRUG, AND COSMETIC ACT
* * * * * * *
CHAPTER III--PROHIBITED ACTS AND PENALTIES
prohibited acts
Sec. 301. The following acts and the causing thereof are
hereby prohibited:
(a) The introduction or delivery for introduction into
interstate commerce of any food, drug, device, tobacco product,
or cosmetic that is adulterated or misbranded.
(b) The adulteration or misbranding of any food, drug,
device, tobacco product, or cosmetic in interstate commerce.
(c) The receipt in interstate commerce of any food, drug,
device, tobacco product, or cosmetic that is adulterated or
misbranded, and the delivery or proffered delivery thereof for
pay or otherwise.
(d) The introduction or delivery for introduction into
interstate commerce of any article in violation of section 404,
415, 505,, 564, or 607.
(e) The refusal to permit access to or copying of any record
as required by section 412, 414, 417(j), 416, 504, 564,
605,703, 704(a), 760, or 761; or the failure to establish or
maintain any record, or make any report, required under section
412, 414(b), 417, 416, 504, 505 (i) or (k), 512(a)(4)(C), 512
(j), (l) or (m), 572(i), 515(f), 519, 564, 605,611, 760, 761,
909, or 920 or the refusal to permit access to or verification
or copying of any such required record; or the violation of any
recordkeeping requirement under section 204 of the FDA Food
Safety Modernization Act (except when such violation is
committed by a farm).
(f) The refusal to permit entry or inspection as authorized
by section 704.
(g) The manufacture within any Territory of any food, drug,
device, tobacco product, or cosmetic that is adulterated or
misbranded.
(h) The giving of a guaranty or undertaking referred to in
section 303(c)(2), which guaranty or undertaking is false,
except by a person who relied upon a guaranty or undertaking to
the same effect signed by, and containing the name and address
of, the person residing in the United States from whom he
received in good faith the food, drug, device, tobacco product,
or cosmetic; or the giving of a guaranty or undertaking
referred to in section 303(c)(3), which guaranty or undertaking
is false.
(i)(1) Forging, counterfeiting, simulating, or falsely
representing, or without proper authority using any mark,
stamp, tag, label, or other identification device authorized or
required by regulations promulgated under the provisions of
section 404 or 721.
(2) Making, selling, disposing of, or keeping in possession,
control, or custody, or concealing any punch, die, plate,
stone, or other thing designed to print, imprint, or reproduce
the trademark, trade name, or other identifying mark, imprint,
or device of another or any likeness of any of the foregoing
upon any drug or container or labeling thereof so as to render
such drugs a counterfeit drug.
(3) The doing of any act which causes a drug to be a
counterfeit drug, or the sale or dispensing, or the holding for
sale or dispensing, of a counterfeit drug.
(j) The using by any person to his own advantage, or
revealing, other than to the Secretary or officers or employees
of the Department, or to the courts when relevant in any
judicial proceeding under this Act, any information acquired
under authority of section 404, 409, 412, 414, 505, 510, 512,
513, 514, 515, 516, 518, 519, 520, 571, 572, 573, 704, 708,
721, 904, 905, 906, 907, 908, 909, or 920(b) concerning any
method or process which as a trade secret is entitled to
protection; or the violating of section 408(i)(2) or any
regulation issued under that section.. This paragraph does not
authorize the withholding of information from either House of
Congress or from, to the extent of matter within its
jurisdiction, any committee or subcommittee of such committee
or any joint committee of Congress or any subcommittee of such
joint committee.
(k) The alteration, mutilation, destruction, obliteration, or
removal of the whole or any part of the labeling of, or the
doing of any other act with respect to, a food, drug, device,
tobacco product, or cosmetic, if such act is done while such
article is held for sale (whether or not the first sale) after
shipment in interstate commerce and results in such article
being adulterated or misbranded.
(m) The sale or offering for sale of colored oleomargarine or
colored margarine, or the possession or serving of colored
oleomargarine or colored margarine in violation of section
407(b) or 407(c).
(n) The using, in labeling, advertising or other sales
promotion of any reference to any report or analysis furnished
in compliance with section 704.
(o) In the case of a prescription drug distributed or offered
for sale in interstate commerce, the failure of the
manufacturer, packer, or distributor thereof to maintain for
transmittal, or to transmit, to any practitioner licensed by
applicable State law to administer such drug who makes written
request for information as to such drug, true and correct
copies of all printed matter which is required to be included
in any package in which that drug is distributed or sold, or
such other printed matter as is approved by the Secretary.
Nothing in this paragraph shall be construed to exempt any
person from any labeling requirement imposed by or under other
provisions of this Act.
(p) The failure to register in accordance with section 510 or
905, the failure to provide any information required by section
510(j), 510(k), 905(i), or 905(j), or the failure to provide a
notice required by section 510(j)(2) or 905(i)(3).
(q)(1) The failure or refusal--
(A) to comply with any requirement prescribed under
section 518, 520(g), 903(b), 907, 908, or 915;
(B) to furnish any notification or other material or
information required by or under section 519, 520(g),
904, 909, or 920; or
(C) to comply with a requirement under section 522 or
913.
(2) With respect to any device or tobacco product, the
submission of any report that is required by or under this Act
that is false or misleading in any material respect.
(3) The failure to comply with any requirement under section
524B(b)(2) (relating to ensuring device cybersecurity).
(r) The movement of a device, drug, or tobacco product in
violation of an order under section 304(g) or the removal or
alteration of any mark or label required by the order to
identify the device, drug, or tobacco product as detained.
(s) The failure to provide the notice required by section
412(c) or 412(e), the failure to make the reports required by
section 412(f)(1)(B), the failure to retain the records
required by section 412(b)(4), or the failure to meet the
requirements prescribed under section 412(f)(3).
(t) The importation of a drug in violation of section
801(d)(1), the sale, purchase, or trade of a drug or drug
sample or the offer to sell, purchase, or trade a drug or drug
sample in violation of section 503(c), the sale, purchase, or
trade of a coupon, the offer to sell, purchase, or trade such a
coupon, or the counterfeiting of such a coupon in violation of
section 503(c)(2), the distribution of a drug sample in
violation of section 503(d) or the failure to otherwise comply
with the requirements of section 503(d), the distribution of
drugs in violation of section 503(e), failure to comply with
the requirements under section 582, the failure to comply with
the requirements under section 584, as applicable, or the
failure to otherwise comply with the requirements of section
503(e).
(u) The failure to comply with any requirements of the
provisions of, or any regulations or orders of the Secretary,
under section 512(a)(4)(A), 512(a)(4)(D), or 512(a)(5).
(v) The introduction or delivery for introduction into
interstate commerce of a dietary supplement that is unsafe
under section 413.
(w) The making of a knowingly false statement in any
statement, certificate of analysis, record, or report required
or requested under section 801(d)(3); the failure to submit a
certificate of analysis as required under such section; the
failure to maintain records or to submit records or reports as
required by such section; the release into interstate commerce
of any article or portion thereof imported into the United
States under such section or any finished product made from
such article or portion, except for export in accordance with
section 801(e) or 802, or with section 351(h) of the Public
Health Service Act; or the failure to so export or to destroy
such an article or portions thereof, or such a finished
product.
(x) The falsification of a declaration of conformity
submitted under section 514(c) or the failure or refusal to
provide data or information requested by the Secretary under
paragraph (3) of such section.
(y) In the case of a drug, device, or food--
(1) the submission of a report or recommendation by a
person accredited under section 523 that is false or
misleading in any material respect;
(2) the disclosure by a person accredited under
section 523 of confidential commercial information or
any trade secret without the express written consent of
the person who submitted such information or secret to
such person; or
(3) the receipt by a person accredited under section
523 of a bribe in any form or the doing of any corrupt
act by such person associated with a responsibility
delegated to such person under this Act.
(z) The dissemination of information in violation of section
551.
(aa) The importation of a prescription drug in violation of
section 804, the falsification of any record required to be
maintained or provided to the Secretary under such section, or
any other violation of regulations under such section.
(bb) The transfer of an article of food in violation of an
order under section 304(h), or the removal or alteration of any
mark or label required by the order to identify the article as
detained.
(cc) The importing or offering for import into the United
States of an article of food or a drug by, with the assistance
of, or at the direction of, a person debarred from such
activity under section 306(b)(3).
(dd) The failure to register in accordance with section 415.
(ee) The importing or offering for import into the United
States of an article of food in violation of the requirements
under section 801(m).
(ff) The importing or offering for import into the United
States of a drug or device with respect to which there is a
failure to comply with a request of the Secretary to submit to
the Secretary a statement under section 801(o).
(gg) The knowing failure to comply with paragraph (7)(E) of
section 704(g); the knowing inclusion by a person accredited
under paragraph (2) of such section of false information in an
inspection report under paragraph (7)(A) of such section; or
the knowing failure of such a person to include material facts
in such a report.
(hh) The failure by a shipper, carrier by motor vehicle or
rail vehicle, receiver, or any other person engaged in the
transportation of food to comply with the sanitary
transportation practices prescribed by the Secretary under
section 416.
(ii) The falsification of a report of a serious adverse event
submitted to a responsible person (as defined under section
604,760, or 761) or the falsification of a serious adverse
event report (as defined under section 760 or 761 or required
under section 605(a)) submitted to the Secretary.
(jj)(1) The failure to submit the certification required by
section 402(j)(5)(B) of the Public Health Service Act, or
knowingly submitting a false certification under such section.
(2) The failure to submit clinical trial information required
under subsection (j) of section 402 of the Public Health
Service Act.
(3) The submission of clinical trial information under
subsection (j) of section 402 of the Public Health Service Act
that is false or misleading in any particular under paragraph
(5)(D) of such subsection (j).
(kk) The dissemination of a television advertisement without
complying with section 503B.
(ll) The introduction or delivery for introduction into
interstate commerce of any food to which has been added a drug
approved under section 505, a biological product licensed under
section 351 of the Public Health Service Act, or a drug or a
biological product for which substantial clinical
investigations have been instituted and for which the existence
of such investigations has been made public, unless--
(1) such drug or such biological product was marketed
in food before any approval of the drug under section
505, before licensure of the biological product under
such section 351, and before any substantial clinical
investigations involving the drug or the biological
product have been instituted;
(2) the Secretary, in the Secretary's discretion, has
issued a regulation, after notice and comment,
approving the use of such drug or such biological
product in the food;
(3) the use of the drug or the biological product in
the food is to enhance the safety of the food to which
the drug or the biological product is added or applied
and not to have independent biological or therapeutic
effects on humans, and the use is in conformity with--
(A) a regulation issued under section 409
prescribing conditions of safe use in food;
(B) a regulation listing or affirming
conditions under which the use of the drug or
the biological product in food is gener